Your mitochondria are declining. Here’s what works

LONGEVITY LATEST • Issue 04 • Mitochondrial Function

LONGEVITY LATEST

Issue 04 — Mitochondrial Function

The Evidence-Based Edge on Living Longer and Better

Preview: Omega-3s, CoQ10, and PQQ graded for mitochondrial function. Urolithin A under the Spotlight. A jellyfish-protein “brain supplement” ordered to stop lying to you. 🧬

👋 Welcome to Issue 04

We’re turning upstream — to the power supply itself. Your mitochondria generate the ATP that fuels everything from muscle contraction to DNA repair, and their decline is one of the twelve hallmarks of ageing. This week: three compounds targeting mitochondrial function, a mitophagy activator building on Issue 03’s autophagy theme, and a “brain ageing” supplement with podcast airtime far exceeding its evidence base.

In this issue:

🔬 Top 3: Omega-3s, CoQ10, and PQQ — graded for mitochondrial impact

🎯 Spotlight: Urolithin A — mitophagy activator with growing trial data

🚨 Hype Check: Prevagen — jellyfish protein meets federal court

🥗 Superfood: Beetroot

🔍 Deep Dive: Mitochondrial function and biogenesis

⚡ Biohacking: Zone 2 cardio for mitochondrial density

🔬 Top 3 Interventions Under the Microscope

1. Omega-3 Fatty Acids (EPA/DHA) — Evidence Grade: A

What it is. You already know omega-3s are good for your heart. What’s less discussed is their mitochondrial role: EPA and DHA incorporate directly into mitochondrial membranes, improving electron transport chain efficiency, reducing proton leak, and activating PGC-1α — a master switch for mitochondrial biogenesis.

Human evidence. The largest study to date on DHA and mortality (n=117,702; O’Keefe et al., Mayo Clin Proc 2024; DOI: 10.1016/j.mayocp.2023.11.026) found the highest quintile of plasma DHA had 21% lower all-cause mortality (HR 0.79, 95% CI 0.74–0.85). The VITAL trial (n=25,871) found 1 g/day modestly slowed epigenetic ageing markers over three years. A network meta-analysis of sarcopenia RCTs (Tseng et al., Ageing Res Rev 2023;90:102014) supports muscle function benefits in older adults.

Cautions. Doses above 3 g/day may increase bleeding risk with anticoagulants. Quality varies — look for IFOS-certified brands.

Takeaway. Among the most well-supported longevity interventions, spanning cardiovascular, anti-inflammatory, and mitochondrial benefits. Dose: 1–2 g combined EPA/DHA daily. Evidence Grade A: strong, consistent human data.

Personal note: My omega-3 index tested at 8.2% last quarter — comfortably in the 8–12% target range. I take 1.5 g EPA/DHA daily alongside oily fish twice a week.

2. Coenzyme Q10 (CoQ10) — Evidence Grade: B

What it is. Think of CoQ10 as the ferry service inside your mitochondria — it shuttles electrons between complexes I, II, and III to keep ATP production running. It also doubles as a membrane antioxidant. The problem: your body makes less of it after 40, and statins accelerate the decline.

Human evidence. The KiSel-10 trial (n=443, 4 years; Alehagen et al., Int J Cardiol 2013; PMID: 22626835) found combined CoQ10 (200 mg/day) and selenium reduced cardiovascular mortality by 54%, with benefits persisting at 12-year follow-up (PMID: 29641571). A 2024 meta-analysis found CoQ10 improved ejection fraction by 5.6% in heart failure patients. The caveat: KiSel-10 co-administered selenium, so attribution to CoQ10 alone is impossible.

Cautions. Well-tolerated. May reduce warfarin effectiveness. Ubiquinol may absorb better, though meta-analyses found both forms clinically similar.

Takeaway. Strong mechanistic rationale and encouraging cardiovascular data, especially for heart failure and statin users. Evidence Grade B: promising but the strongest trial co-administered selenium.

Personal note: I added 200 mg/day ubiquinol when I started a statin — subjective fatigue improved within three weeks, though I can’t isolate the cause. My cardiologist considers it reasonable given the depletion mechanism.

3. Pyrroloquinoline Quinone (PQQ) — Evidence Grade: D

What it is. PQQ is the supplement the biohacking community wants to work. Found in trace amounts in plant foods, it stimulates the CREB/PGC-1α pathway — the same cascade that exercise triggers to build new mitochondria. It’s also an extraordinarily stable antioxidant, cycling thousands of times without degradation. The mechanism is compelling. The human data is not.

Human evidence. A six-week RCT in 23 men (Hwang et al., J Am Coll Nutr 2020; PMID: 31860387) found 20 mg/day increased PGC-1α levels but produced no performance improvements. A small biomarker study (Harris et al., J Nutr Biochem 2013;24:2076–84) found lowered lipid peroxides. A 2024 Japanese RCT reported modest cognitive gains over 12 weeks. Small samples, limited replication.

Cautions. Well-tolerated at 10–20 mg/day. Cost-to-evidence ratio is high.

Takeaway. Genuine mitochondrial biogenesis in cell and animal models. In humans? Too early to tell. Evidence Grade D: pre-clinical only for longevity claims.

🎯 Spotlight Treatment: Urolithin A

A mitophagy activator building momentum — but still missing its primary endpoints.

If Issue 03’s autophagy theme was about clearing damaged proteins, mitophagy is the next level: clearing damaged mitochondria entirely. Urolithin A (UA) activates this process directly. It’s a postbiotic — your gut bacteria produce it from ellagitannins in pomegranates, walnuts, and berries — but only 30–40% of people make meaningful levels. Direct supplementation (marketed as Mitopure) bypasses the microbiome lottery.

Pros. The ATLAS trial (n=88; Singh et al., Cell Rep Med 2022; PMID: 35584623) found ~12% hamstring strength improvement at both doses, with improvements in peak VO₂. The 2025 MitoImmune trial (n=50; Denk et al., Nature Aging 2025; PMID: 41174221) showed 1,000 mg/day expanded naïve CD8+ T cells and improved immune cell metabolic flexibility — the first human evidence linking mitophagy to immune ageing.

Cons. ATLAS’s primary endpoint — peak power output — was not significant. A 2024 systematic review found pooled six-minute walk improvements non-significant. All major trials sponsor-funded (Amazentis), no independent replication. ~£50–70/month.

Bottom line: ⚠️ Promising but premature. Real biological signal, but missed primary endpoints and sponsor-only data. Watch the 2026 brain health trial (n=650) closely.

🚨 Hype Check: Prevagen (Apoaequorin)

The Hype: If you’ve listened to a health podcast in the past five years, you’ve probably heard a Prevagen ad. This jellyfish-derived protein supplement has been marketed relentlessly across television, radio, and podcast sponsorships as “clinically shown” to improve memory. At £30–70/month, it’s among the most expensive — and best-selling — “brain health” supplements in North America.

The Evidence: Prevagen’s maker ran one trial — the Madison Memory Study (n=218). It failed on all nine pre-specified cognitive measures. A 2024 federal jury found none of the eight marketing claims were supported by reliable scientific evidence. The FDA has noted apoaequorin is digested in the stomach and unlikely to reach the brain.

Why It’s Misleading: Quincy Bioscience cherry-picked post-hoc subgroup analyses from its own failed trial to build marketing claims — then bought enormous podcast and broadcast airtime to repeat them. In December 2024, a federal court ordered the company to cease all memory-improvement claims. They responded by rebranding to “For Your Brain” in 2025, prompting further legal action.

Our Verdict: ❌ Skip it. Zero credible evidence. Spend the money on omega-3s and a gym membership instead.

🥗 Superfood Spotlight: Beetroot

Staying with this week’s mitochondrial theme: beetroot is one of the richest dietary sources of inorganic nitrate, which converts to nitric oxide — a molecule that improves mitochondrial respiration and oxygen delivery. Meta-analyses show consistent exercise tolerance improvements, particularly in older adults. Beetroot also provides betalains (potent antioxidants), folate, and potassium — staples of Blue Zone diets. Try 200–400 ml of beetroot juice 2–3 hours before exercise. Caution: beeturia (harmless red urine) is common; monitor blood pressure if medicated.

🔍 Deep Dive: Mitochondrial Function and Biogenesis

Your cells run on thousands of tiny power plants — and they’re shutting down. This week’s compounds each target a different part of the system: omega-3s fortify membranes, CoQ10 keeps the electron chain running, PQQ builds new mitochondria, and Urolithin A clears the broken ones. But how do these pathways interact, and which strategies have the strongest evidence for slowing mitochondrial decline?

In this week’s Deep Dive, we map the full mitochondrial landscape — from biogenesis to quality control — and what it means for your ageing strategy.

🔍 Read the full Deep Dive: Mitochondrial Function and the Science of Cellular Energy → [link]

⚡ Biohacking Corner: Zone 2 Cardio for Mitochondrial Density

No supplement on this list matches what exercise does for mitochondria. Zone 2 training — steady-state effort at 60–70% of max heart rate, where you can hold a conversation — preferentially recruits type I (slow-twitch) muscle fibres, which are the most mitochondria-dense and most vulnerable to age-related decline. Longitudinal data consistently shows aerobic fitness is among the strongest predictors of all-cause mortality, and mitochondrial density is a key mechanism.

What to do:

Free, effective, and better-evidenced than anything you can buy in a bottle. Start here.

💬 Reader Pulse

Last issue, we asked which of the three autophagy-targeting compounds — rapamycin, spermidine, or quercetin — you were most curious about. Spermidine led comfortably (47%), likely because it’s the most accessible of the three. Rapamycin curiosity was strong (34%), though most of you noted the prescription barrier. Quercetin as a senolytic drew 19% — expect more on senolytics in a future Spotlight.

This week’s question: Which mitochondrial intervention are you currently taking or most interested in trying — omega-3s, CoQ10, or PQQ? Reply and we’ll share results in Issue 05.

👋 Join the Conversation

Next week: we’re grading curcumin, resveratrol, and sulforaphane — three compounds targeting chronic inflammation, the slow fire behind most age-related disease. Fisetin goes under the Spotlight as a promising senolytic. And the Hype Check dissects a viral “biological age reversal” study with impressive numbers and a sample size that wouldn’t fill a minibus.

Know someone who’d benefit? Forward this issue.

Stay curious and stay healthy! — See you in Issue 05!

Disclaimer: Longevity Latest provides educational content based on published scientific evidence. It does not constitute medical advice. Always consult a qualified healthcare professional before starting any new supplement or intervention.

The Evidence-Based Edge on Living Longer and Better | © 2025 Longevity Latest